Unknown

Dataset Information

0

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.


ABSTRACT: Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, prospective, non-controlled, multi-center studies.Subjects >4 years of age received SC IgG replacement at a weekly dose equivalent of 108 % of their previous intravenous (IV) dose, facilitated by prior injection of 75 U/g IgG of rHuPH20. Starting with weekly SC infusions, the interval was increased (ramped-up) to a 3- or 4-week schedule.Eighty-three subjects (24?

SUBMITTER: Wasserman RL 

PROVIDER: S-EPMC4940441 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Wasserman Richard L RL   Melamed Isaac I   Stein Mark R MR   Engl Werner W   Sharkhawy Marlies M   Leibl Heinz H   Puck Jennifer J   Rubinstein Arye A   Kobrynski Lisa L   Gupta Sudhir S   Grant Andrew J AJ   Ratnayake Anoshie A   Richmond Wendell G WG   Church Joseph J   Yel Leman L   Gelmont David D  

Journal of clinical immunology 20160525 6


<h4>Purpose</h4>Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, prospective, non-controlled, multi-center studies.<h4>Methods</h4>Subjects >4 years of age received SC IgG replacement at a weekly dose equivalent of 108 % of their previous intravenous (IV) dose, facilitated by prior injection of 75 U/g IgG of rH  ...[more]

Similar Datasets

| S-EPMC10739571 | biostudies-literature
| 2283030 | ecrin-mdr-crc
| S-EPMC7858210 | biostudies-literature
| S-EPMC3937544 | biostudies-literature
| S-EPMC7788039 | biostudies-literature
| S-EPMC10275800 | biostudies-literature
| S-EPMC10088636 | biostudies-literature
| S-EPMC6394283 | biostudies-literature
| S-EPMC7846525 | biostudies-literature
| S-EPMC4471820 | biostudies-literature